Share this article
Share this article
ResearchAndMarkets.com s offering.
The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate the pandemic. Disruptions to healthcare systems and the management of chronic diseases has resulted in patients having difficulty seeing HCPs and receiving treatment, including for autoimmune and inflammatory conditions, especially as many of these immunological disorders require ongoing therapy.
Immunological disorders whose treatment has been disrupted include psoriasis, rheumatoid arthritis, inflammatory bowel disease, and others.
The key objectives of this report are to:
GLocalMind completes 10-year in healthcare business
GLocalMind completes 10-year in healthcare business
10 December 2020 | News
Image source: Shutterstock
GLocalMind, a leading healthcare fieldwork and analysis company serving the healthcare ecosystem, has successfully completed 10 years in the business. With its global headquarters in the US and operations headquarters in India, GLocalMind has access to healthcare professionals in 57 Countries across 86 Specialties and 60 Medical Conditions and over 1.5 million panelists, making them a familiar name in the healthcare research sector the world over.
They provide access to healthcare stakeholders including physicians, patients and payers by way of their panels, partners and custom recruitment. Their client base includes top Global Market Research Companies, Hospitals, Pharma Companies, Healthcare Consulting Companies, Life Sciences Companies and Medical Device Companies.